Abstract:We characterized the inhibition of Neisseria gonorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth known as ETX0914 (Entasis Therapeutics)), a novel spiropyrimidinetrione antibacterial compound that is currently in clinical trials for treatment of drug-resistant gonorrhea. AZD0914 has potent bactericidal activity against N. gonorrhoeae, including multidrug-resistant strains and key Gram-positive, fastidious Gram-negative, atypical, and anaerobic bacterial species (Huband, M. D., Bradford, P. A., Otterson, L. G., Basrab, G. S., Giacobe, R. A., Patey, S. A., Kutschke, A. C., Johnstone, M. R., Potter, M. E., Miller, P. F., and Mueller, J. P. (2014) In Vitro Antibacterial Activity of AZD0914: A New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-positive, Fastidious Gram-negative, and Atypical Bacteria. Antimicrob. Agents Chemother. 59, 467–474). AZD0914 inhibited DNA biosynthesis preferentially to other macromolecules in Escherichia coli and induced the SOS response to DNA damage in E. coli. AZD0914 stabilized the enzyme-DNA cleaved complex for N. gonorrhoeae gyrase and topoisomerase IV. The potency of AZD0914 for inhibition of supercoiling and the stabilization of cleaved complex by N. gonorrhoeae gyrase increased in a fluoroquinolone-resistant mutant enzyme. When a mutation, conferring mild resistance to AZD0914, was present in the fluoroquinolone-resistant mutant, the potency of ciprofloxacin for inhibition of supercoiling and stabilization of cleaved complex was increased greater than 20-fold. In contrast to ciprofloxacin, religation of the cleaved DNA did not occur in the presence of AZD0914 upon removal of magnesium from the DNA-gyrase-inhibitor complex. AZD0914 had relatively low potency for inhibition of human type II topoisomerases α and β.

The role of prokaryotic argonautes in resistance to type II topoisomerases poison ciprofloxacin

Catalytically inactive long prokaryotic Argonaute systems employ distinct effectors to confer immunity via abortive infection

A short prokaryotic Argonaute activates membrane effector to confer antiviral defense

DNA-targeting short Argonautes complex with effector proteins for collateral nuclease activity and bacterial population immunity

The prokaryotic Argonaute proteins enhance homology sequence-directed recombination in bacteria

The Expanding Roles of Argonautes: RNA Interference, Splicing and Beyond

Structural and mechanistic insights into a mesophilic prokaryotic Argonaute

Atypical bacterial Argonautes regulate antiphage defense

Prokaryotic Argonaute nuclease cooperates with co-encoded RNase to acquire guide RNAs and target invader DNA

Argonaute of the archaeon Pyrococcus furiosus is a DNA-guided nuclease that targets cognate DNA

Prokaryotic Argonaute Proteins as a Tool for Biotechnology

A programmable omnipotent Argonaute nuclease from mesophilic bacteria Kurthia massiliensis

DNA interference by a mesophilic Argonaute protein, CbcAgo

Unusual Guide-binding Pockets in RNA-targeting pAgo Nucleases

The nuclease-associated short prokaryotic Argonaute system nonspecifically degrades DNA upon activation by target recognition

Nucleic-acid-triggered NADase activation of a short prokaryotic Argonaute

ppGpp and RNA-polymerase backtracking guide antibiotic-induced mutable gambler cells

Structures and functions of short argonautes

Dynamic Control of Argonautes by a Rapidly Evolving Immunological Switch

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914

Structural and mechanistic insights into an archaeal DNA-guided Argonaute protein